Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index; 5 of the 14 sources its claims cite were checked for support.

Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence

Open access

Abstract

Aims/hypothesis: Glucagon-like peptide 1 (GLP-1) agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors are novel drugs which have recently seen rapid uptake in the treatment of type 2 diabetes and obesity. The paucity of data regarding their safety during pregnancy and lactation causes a dilemma for the physician. The aim of the present study was to systematically review all available data on the offspring effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation. Methods: 2023. Eligible studies investigating the safety (including congenital anomalies, fetal growth, perinatal demise) in animals or humans, or reporting the degree of transfer of these drugs to the fetus, breast milk or breastfed neonate. Two reviewers independently assessed and selected studies for inclusion and subsequently resolved discrepancies by discussion. Results: We included 39 records (n=9 theoretical; based on drug properties, n=7 human; n=23 animal, including 76 human offspring, and an unknown number of animal offspring as these numbers could not be retrieved from the FDA and EMA product information). In animal studies, GLP1-agonists were associated with reduced fetal weight and/or growth, delayed ossification and skeletal variants, usually associated with a reduction in maternal weight gain and decreased food consumption. Exendin-4 (GLP1-agonist) was not transported across the maternal-fetal placental interface. In human studies, exenatide (GLP1-agonist) showed a fetal-to-maternal peptide concentration ratio of ≤ 0.017 in ex vivo human placental perfusion in a single placenta. Liraglutide (GLP1-agonist) showed no significant maternal to fetal transfer at least 3.5 hours after maternal exposure in a human study with one subject. In animal studies, GLP-1 agonists were excreted in breast milk; human data on excretion were not available. In animal studies, SGLT2 inhibitors were generally safe during the first trimester but exposure during postnatal day 21 to 90 in juvenile rats, a period coinciding with the late second and third trimester of human renal development, caused dilatation of the renal pelvis and tubules. Human data consisted of a pharmaceutical database of inadvertent pregnancies during SGLT2 inhibitor use, which found an increase in miscarriages and congenital malformations. In animal studies SGLT2 inhibitors were excreted in breast milk and affected neonatal growth, but human data are not available. Conclusion/interpretation: We found evidence for adverse offspring effects of GLP-1 agonists and SGLT2 inhibitors also in human studies. Our findings broadly support the advice to discontinue GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation, and also support the ongoing registration of pregnancy outcomes in pharmacological databases since the amount of available data is scarce and mostly limited to animal studies. Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=219877.

Overview

CoChat Summary

TL;DR

This systematic review found adverse offspring effects of GLP-1 agonists and SGLT2 inhibitors in animal studies and limited human data, broadly supporting discontinuation during pregnancy and lactation. Available evidence is scarce, mostly animal-based, and human lactation data are absent.

Key findings

  • GLP-1 agonists in animal studies were associated with reduced fetal weight/growth, delayed or irregular ossification, skeletal variants, reduced embryonic survival, and major congenital anomalies; semaglutide in rats caused visceral abnormalities and major skeletal malformations. Exendin-4 was not transported across the placenta in healthy pregnant mice, liraglutide showed no significant maternal-to-fetal transfer at least 3.5 hours after exposure in one human subject, and exenatide had a fetal-to-maternal peptide concentration ratio of ≤0.017 in ex vivo human placental perfusion.
  • SGLT2 inhibitors were generally not developmentally toxic during first-trimester organogenesis in animals except canagliflozin, which caused metatarsal ossification delays. Exposure on postnatal day 21–90 in juvenile rats, coinciding with late second/third-trimester human renal development, caused dilatation of the renal pelvis and tubules, with reversibility varying by drug. Human pharmaceutical database data found an increase in miscarriages and congenital malformations; for dapagliflozin, 8 reported pregnancy outcomes included 1 congenital hydrocephalus, 2 encephalocele, and 1 infant with talipes, renal aplasia and oesophageal atresia.
  • In animal lactation studies, GLP-1 agonists were excreted in milk (exenatide ≤2.5% of maternal plasma; semaglutide 8.3–33%; lixisenatide 9.4%; liraglutide 50%) and caused reduced fetal/neonatal growth. SGLT2 inhibitors were also excreted in animal milk and affected neonatal growth, but no human lactation data were available for either drug class.
  • The review included 39 records per the abstract (n=9 theoretical, n=7 human, n=23 animal, including 76 human offspring and an unknown number of animal offspring); the results section separately reports 26 GLP-1 agonist records and 16 SGLT2 inhibitor records.

Methods

  • Systematic review searching PubMed, clinicaltrials.gov, FDA and EMA product information from inception up to 19 April 2022 without language restrictions; the search was later updated to include Embase and Cochrane, and the authors contacted the Netherlands Pharmacovigilance Centre Lareb and the Teratology Information Service of Switzerland.
  • Eligible studies investigated safety outcomes (congenital anomalies, fetal growth, perinatal demise) in animals or humans, or reported transfer of these drugs to fetus, breast milk, or breastfed neonate; animal and human studies including case reports were included.
  • Two reviewers independently selected studies and resolved discrepancies by discussion; one reviewer extracted data and assessed quality, with SYRCLE’s risk of bias tool used for animal studies. Out of 1436 unique records, 1372 were excluded.

Limitations

  • Stated: the major limitation is limited availability of both animal and human studies; human studies had small numbers and often lacked data on BMI, age, smoking, drug dose, administration time, and trimester of exposure, and lacked long-term neonatal follow-up.
  • Stated: EMA/FDA data extraction was limited to Europe and the USA, so data from other continents were not captured.
  • Evident from the text: all included animal studies had a high risk of bias; no human lactation studies were found; and no data were received from Lareb or the Swiss TIS.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fendo.2023.1215356

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 PRISMA flowchart.
Figure 1 PRISMA flowchart.CC BY · PubMed Central

Verification

Claims the paper makes

4 Valid · 4 Not valid · 12 Not checked · 32 Own results and interpretations

28 more claims

Create a free account to see all 52 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 13
  • Probably not a substantial claim. 10
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 41 references

Research works printed but not linked: 1

  1. Ivanišević, 2018, Pregnancy outcome and liraglutide levels in serum and umbilical vein blood of a woman with type 2 diabetes. A case report, Gynaecol Perinatol, 27

Cited by

See all 174

Metadata

Authors
Muller, D. R. P., Stenvers, D. J., Malekzadeh, A., Holleman, F., Painter, R. C., & Siegelaar, S. E.
Affiliations
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Amsterdam University Medical Centers (NL)
Corresponding author
Muller, Dion R. P.
Venue
Frontiers in Endocrinology
Published
2023-10-10
Volume
14
Pages
1215356-1215356
ISSN
1664-2392 (ISSN-L)
OpenAlex
W4387477465
Cited by
174
References
41
Citations by year
2026: 63 · 2025: 69 · 2024: 42
FWCI
8.60
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (acceptedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
Keywords
GLP-1 receptor agonists, SGLT2 inhibitors, pregnancy, lactation, drug safety, offspring outcomes, congenital malformations, fetal growth, placental transfer, breast milk excretion, exenatide, exendin-4, liraglutide, dapagliflozin, empagliflozin, drug-induced nephrotoxicity
MeSH terms
Liraglutide, Sodium-Glucose Transporter 2 Inhibitors, Exenatide, Animals, Breast Feeding, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Lactation, Placenta, Pregnancy, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. https://app.cochat.ai/papers/10.3389/fendo.2023.1215356
The paper
Muller, D. R. P., Stenvers, D. J., Malekzadeh, A., Holleman, F., Painter, R. C., & Siegelaar, S. E. (2023). Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2023.1215356

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.